Once I start taking talazoparib/talazopanib, can I stop taking it?

Talazoparib is an oral PARP inhibitor widely used to treat patients with deleterious or suspected deleterious BRCA mutations and HER2-negative locally advanced or metastatic breast cancer. According to the recommendations of the FDA and multiple national cancer treatment guidelines (such as NCCN and ESMO), this drug is a continuous treatment drug and usually needs to be continued until the disease progresses or intolerable toxic reactions occur. In international clinical practice, patients are not recommended to interrupt talazoparib treatment without authorization, especially in the early stages of treatment or in the stage of significant efficacy.

The mechanism of action of talazoparib is based on inhibiting PARP enzyme, blocking the DNA damage repair process, thereby inducing apoptosis in cancer cells with BRCA mutations. This mechanism requires the drug to continuously maintain its concentration in the body to maintain the therapeutic effect. Once the drug is stopped without authorization, the cancer cells may regain their ability to repair, leading to disease progression and even an increased risk of drug resistance. In clinical practice in the United States, if a patient needs to discontinue medication, a doctor usually must evaluate his or her clinical indicators, imaging results, and side effects, and decide whether to temporarily or permanently discontinue the medication based on individual circumstances.

However, not all cases require mandatory continued treatment. According to data provided by Pfizer and the American Cancer Society, when patients experience severe adverse reactions (such as bone marrow suppression, severe fatigue, uncontrollable nausea and vomiting, etc.), doctors may recommend temporarily stopping the drug, reducing the dose, or providing supportive treatment. If symptoms improve after adjustment, talazoparib may be reintroduced. In addition, in some clinical trials, some patients choose to observe after achieving complete remission, but this approach has not yet become a guideline recommendation and is still an exploratory strategy.

In general, once you start taking talazoparib, it is not recommended to stop taking it yourself. Patients should undergo regular hematological examinations and imaging follow-up, and make dosage adjustments or decisions about whether to discontinue the drug according to the doctor's recommendations. Unauthorized discontinuation of medication may have serious consequences for disease control, especially when the tumor is not yet stable or in remission.

Reference materials:https://www.talzenna.com/